Tony Kingsley, Stablix CEO (Scholar Rock)

Ver­tex buys in on Sta­blix's pro­tein sta­bi­liza­tion ap­proach in re­search and li­cens­ing deal

Rough­ly two years af­ter Sta­blix em­barked on a mis­sion to sta­bi­lize cer­tain pro­teins whose in­suf­fi­cien­cy leads to dis­ease, Ver­tex Phar­ma­ceu­ti­cals an­nounced it’s com­ing along for the ride.

Sta­blix and Ver­tex un­veiled a col­lab­o­ra­tion on Tues­day that gives Ver­tex an ex­clu­sive li­cense to cer­tain mol­e­cules dis­cov­ered un­der the pact. Sta­blix has billed its plat­form as a “first-in-cat­e­go­ry” ap­proach that’s es­sen­tial­ly the in­verse of PRO­TACs. The idea is to re­cruit en­zymes called deu­biq­ui­ti­nas­es, or DUBs, to re­store use­ful pro­teins for po­ten­tial use in rare dis­eases, on­col­o­gy and im­munol­o­gy. Sta­blix is call­ing their drugs RESTORACs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.